The umbilical cord provides a rich source of primitive mesenchymal stem cells (human umbilical cord mesenchymal stem cells (HUMSCs)), which have the potential for transplantation-based treatments of Parkinson's Disease (PD). Our pervious study indicated that adenovirus-associated virus-mediated intrastriatal delivery of human vascular endothelial growth factor 165 (VEGF 165) conferred molecular protection to the dopaminergic system. As both VEGF and HUMSCs displayed limited neuroprotection, in this study we investigated whether HUMSCs combined with VEGF expression could offer enhanced neuroprotection. HUMSCs were modified by adenovirus-mediated VEGF gene transfer, and subsequently transplanted into rotenone-lesioned striatum of hemiparkinsonian rats. As a result, HUMSCs differentiated into dopaminergic neuron-like cells on the basis of neuron-specific enolase (NSE) (neuronal marker), glial fibrillary acidic protein (GFAP) (astrocyte marker), nestin (neural stem cell marker) and tyrosine hydroxylase (TH) (dopaminergic marker) expression. Further, VEGF expression significantly enhanced the dopaminergic differentiation of HUMSCs in vivo. HUMSC transplantation ameliorated apomorphine-evoked rotations and reduced the loss of dopaminergic neurons in the lesioned substantia nigra (SNc), which was enhanced significantly by VEGF expression in HUMSCs. These findings present the suitability of HUMSC as a vector for gene therapy and suggest that stem cell engineering with VEGF may improve the transplantation strategy for the treatment of PD.
INTRODUCTION
Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting 107-187 people per 100 000 population. 1 In China, PD affects 1.7% of the population aged 65 years or older. 2 PD patients suffer from rest, rigidity, bradykinesia and postural abnormalities. Current pharmacotherapies only provide temporary relief from early symptoms without stopping disease progression, and the beneficial effects wear off with long-term use. Moreover, nonmotor symptoms, including cognitive, autonomic and psychiatric symptoms, are not sufficiently ameliorated by current therapies. Although there are many promising candidate neuroprotective agents based on pathological and laboratory studies, it is not yet possible to determine whether any drug has a disease-modifying effect on PD. 3, 4 Thus, any treatment that can reverse or stop disease progression is critically needed.
At present, replacement of the progressively degenerated nigrostriatal dopaminergic (DA) neurons through transplantation is considered to have the most potential as a therapy. 3, 5 It is acknowledged that stem cells used for transplantation in neurodegenerative diseases such as PD should be reliable and easily accessible, legally and ethically non-controversial, and have low immunogenicity. 6 Several previous studies have focused on the treatment effectiveness of embryonic stem cells and neural stem cells in parkinsonian animal models. However, embryonic stem cells have associated caveats, including formation of teratomas 7 and elicitation of immune rejection in transplantation, 3 and the supply of human neural stem cells is limited. Human umbilical cord mesenchymal stem cells (HUMSCs) seem to meet all these requirements and have already manifested therapeutic potential in a PD model. 8 However, information on the differentiation fate of HUMSCs after transplantation is sparse, and converting these cells into a stable neuron phenotype remains unexplored. Furthermore, safety is still the first factor to be considered during therapeutic use of stem cells, especially in terms of the stem-cell tumorigenesis problem. 9 ,10 Thus, we still need to assess the safety of HUMSC treatment for which there is a lack of published evidence.
On the other hand, modulation of neurotrophic factors may reduce dopaminergic vulnerability. The loss of neurotrophic factors, such as vascular endothelial growth factor (VEGF) generated by the vascular system, has been suggested as one of the causes of neurodegenerative disease. 11 VEGF was proven to promote the growth and survival of DA neurons in ventral mesencephalon explants 12, 13 and animal models for PD. 14, 15 Our previous work indicated that relatively low-level expression of VEGF mediated by adeno-associated virus in the striatum protected the DA neurons of parkinsonian rats. 16 In this study, we attempt to develop a more effective neurorestorative and neuroregenerative therapy on the basis of a combination of VEGF expression and HUMSC therapy.
In this study, a new method to isolate and culture HUMSCs, which is easy to master and of high reproducibility, provided an efficient alternative to traditional enzymatic digestion-based methods. In addition, safety, reliability and differentiation of HUMSCs after transplantation were assessed.
RESULTS

Characterization of HUMSCs
Distinctive morphology and surface antigens of HUMSCs. After the initial 9-12 days of primary culture, a small population of single HUMSCs adhered to the plastic surface (Figure 1a) , were similar in shape to long spindle-shaped fibroblasts, subsequently formed colonies and became confluent (Figures 1a-d) . After being cultured for another 2 weeks, B1Â10 7 HUMSCs were harvested from every 5 cms of umbilical cord, and the number of HUMSCs doubled every 2 or 3 days (data not shown). The HUMSCs were positive for CD10 (24.33%), CD13 (98.68%) and CD49e (99.17%), but negative for hematopoietic markers CD14, CD45 and HLA-DR (MHC II) (Figure 1i ), myeloid marker CD33 and endothelial/hematopoietic stem cell marker CD34. By immunofluorescent staining, HUMSCs were further validated to be positive for CD44 (Figure 1g ) and negative for CD34 and CD45 (Figure 1h ), indicating that HUMSCs are mesenchymal stem cells and not hematopoietic or endothelial cells. In HUMSCs, the extensiveness of rough endoplasmic reticulum and generous numbers of ribosomes on the rough endoplasmic reticulum were observed using transmission electron microscopy. In addition, HUMSCs had a high nucleo-cytoplasmic ratio and a large nucleolus (Figures 1e and f) , indicating that HUMSC is a kind of cell with vigorous metabolism and still in an early stage.
Neuronal differentiation of HUMSCs. When HUMSCs were cultured under conditions favorable for adipogenic, neurogenic or osteogenic differentiation, the expanded cells were highly differentiated and the appearance of lineage-specific cell types was easily distinguished under an inverted phase contrast microscope (Supplementary Figure S1a Enzyme-linked immunosorbent assay data indicated that the release of VEGF into medium from Ad-VEGF-EGFP-infected HUMSCs was in a MOI-dependent manner (Figure 2h ). The VEGF in the medium of Ad-EGFP-infected HUMSCs was 0.20 ± 0.04 ng ml À1 48 h after adenoviruses infection, whereas it was 9.78 ± 0.82 ng ml À1 in the medium of Ad-VEGF-EGFP (400 MOI)-treated HUMSCs. Striatal VEGF levels on an average were 17.07 ± 2.50, 16.53 ± 1.20, 24.72 ± 1.68 and 58.74 ± 10.38 ng per mg of wet tissue in the contralateral striatum of each group, in the lesioned side of the saline group, Ad-EGFP group and Ad-VEGF-EGFP group, respectively, 12 weeks after transplantation. Striatal VEGF levels were 49.58 and 255.46% higher in the Ad-EGFP and Ad-VEGF-EGFP groups compared with that in the saline group (Figure 4am , and the efficiency of infection was 91.9 ± 2.6% at MOI 400 pfu per cell at 48 h of infection (i). MTT assay showed that MOI 400 pfu of cell promoted HUMSC proliferation without any side effects (g), which could be attributed to the VEGF secretion into the medium from Ad-VEGF-EGFP-infected HUMSCs (h). Immunofluorescence with confocal microscopy was used to observe the coexpression of EGFP and VEGF (VEGF 165 antibody and CY3-conjugated donkey antimouse IgG), and nuclear matter was stained by Hoechst33258 (j-m). Statistics consisted of one-way ANOVA; *Po0.05, compared with the control group.
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Effect of transplantation on parkinsonian rats HUMSCs and VEGF-expressing HUMSCs improved apomorphineinduced rotations in parkinsonian rats. A unilateral rotenone lesion of the VTA and the SNc induced turning behavior as expected in all animals after apomorphine treatment. 17 In the saline group, a progressive degradation in performance was observed following rotenone infusion. However, the lesioned rats receiving a HUMSC transplant showed a significant decrease in the number of rotations (Figure 3a) . Our data showed that at the twelfth posttransplant week, the Ad-EGFP group decreased rotations by 53.21%, whereas the Ad-VEGF-EGFP group decreased rotations by 72.44%, compared with the saline group. In some Ad-VEGF-EGFP group animals, the rotations were decreased by more than 90%.
HUMSCs and VEGF-expressing HUMSCs prevent tyrosine hydroxylase (TH) immunoreactivity decrease in the striatum and SNc. Asymmetric staining of TH in the striatum and the SNc showed evidence of the toxic effect of rotenone on DA neurons and the nigrostriatal tract on the side ipsilateral to the injection site (Figures 3d, e, h and i) . The quantification study indicated that rotenone induced the degen- 
DISCUSSION
In this study, we showed that intrastriatal infusion of either HUMSCs or VEGF-expressing HUMSCs to rotenone-induced parkinsonian rats resulted in a reduction of apomorphine-induced rotations, and a revival of TH immunoreactivity in the lesioned striatum and SNc, which indicated therapeutic effects of these cells in parkinsonian rats. Our primary finding is that VEGF protein expression in HUMSCs enhanced their treatment effectiveness, as further behavioral recovery and TH immunoreactivity protection were observed in the Ad-VEGF-EGFP group compared with the Ad-EGFP group. These data suggest that VEGF gene-modified HUMSCs confer more powerful protection for PD, and VEGF-expressing HUMSCs are an improved transplantation and gene therapy strategy for PD. For the first time, we showed that HUMSCs were differentiated into TH-, Nestin-, NSE-and GFAP-positive cells after transplantation into a parkinsonian corpus striatum. Interestingly, VEGF promoted HUMSC differentiation into TH-, NSE-and Nestin-positive cells, but inhibited HUMSC conversion into GFAP-positive cells, which demonstrated VEGF expression enhancing the dopaminergic differentiation of HUMSCs in vivo. TH and EGFP coexpression was observed in cells of the lesioned SNc, indicating that HUMSCs could migrate from corpus striatum to the SNc and differentiate into TH-positive cells in the lesioned SNc. Importantly, none of the 20 animals under HUMSCs treatment showed immunological rejection throughout the entire period of 12 weeks, and no tumor-like formations were detected among those animals at the end of 12 weeks.
Another interesting finding was that Ad-EGFP-HUMSC transplantation significantly increased VEGF level in the striatum, as shown by enzyme-linked immunosorbent assay and VEGF immunohistochemistry staining, which was similar to a previous study that showed human bone marrow-derived mesenchymal stem cells could stimulate the expression of brain-derived neurotrophic factor. 18 Moreover, the striatal VEGF level in the Ad-VEGF-EGFP group was significantly higher than that in the saline group and Ad-EGFP group. Previous studies showed the direct and indirect neuroprotective effects of VEGF. [14] [15] [16] 19, 20 Directly, VEGF is neuroprotective and even induces neurogenesis of DA neurons, [14] [15] [16] 21 and VEGF displayed the neuroprotective effects by activating VEGF receptor 1, VEGF receptor 2 and the neuropilin receptor. 21 Other well-known functions of VEGF include angiogenesis, accentuation of vessel permeability and glial proliferation, which promote the expression of neurotrophic factors like glial cell line-derived neurotrophic factor. [14] [15] [16] 21 In this study, immunofluorescence staining of GFAP proximal to the pin track showed the proliferation of GFAP-positive cells compared with contralateral striatum, the same findings as our previous study. 16 These data are evidence that the activity of gliocytes and the increased glial cell line-derived neurotrophic factor levels contribute to the protective effect. 16 Further, we found that VEGF not only protected DA neurons but also promoted directional differentiation of HUMSCs into TH-positive cells.
In this study, we introduced a simple, reliable and effective method of preparing HUMSCs. HUMSCs have been isolated by enzymatic digestion methods 22 and by the culturing of minced tissue. 23 However, the majority of subsequent studies used enzymatic digestion methods, 8, [24] [25] [26] and the concentration and species of enzyme used for digestion varied dramatically among different studies. Using the method we described, HUMSCs could be isolated successfully from every umbilical cord we collected, suggesting that the culturing of minced tissue method is reliable for the isolation of HUMSCs. Moreover, this method is easy to perform. HUMSCs share many surface markers with adult MSCs. Consistent with previous reports, 8, 27, 28 we found that HUMSCs are positive for CD13, CD29, CD44, CD90 and CD10 and negative for CD14, CD28, CD31, CD34, CD45, CD56 and CD133. Data from transmission electron microscopy, the 'gold standard' for the morphology of cells, showed the extensiveness of rough endoplasmic reticulum and generous numbers of ribosomes on the rough endoplasmic reticulum, demonstrating that HUMSC is a type of early-stage cell and is capable of rapid expansion and long-term survival. Successful adipogenic, osteogenic and neurogenic differentiation further validated the pluripotency of HUMSCs, indicating the functional characteristic of HUMSC as a kind of stem cell, as also observed for MSC in previous studies. 27, 28 For the parkinsonian animal model, we used the rotenone-based stereotaxic model for the symptoms to progress gradually until 24 weeks, recapitulating the slow and specific loss of DA neurons and better mimicking the clinical features of idiopathic PD. 17 Previous studies failed to provide evidence of neuronal differentiation of HUMSCs after transplantation. 8, 24 In the present study, EGFP was used as a primary stem cell label. Furthermore, mouse monoclonal antibodies were used to detect the expression of specific human VEGF-expressing HUMSC treatment for PD N Xiong et al original Nestin, NSE, GFAP, TH and VEGF. The expression of all these markers in the striatum was significantly different between the Ad-EGFP group and the Ad-VEGF-EGFP group. For example, the percentage of human original NSE-positive cells was 80 ± 10% in the Ad-VEGF-EGFP group, but only 61 ± 10% in the Ad-EGFP group. These data by no means indicate that 80±10% of the HUMSCs converted to NSE-positive cells, as the adenovirus-mediated nongenetically modified cells were unable to maintain long-term expression of exogenous genes. Portions of HUMSCs did not express EGFP after transplantation for 12 weeks; namely, the total number of EGFPlabeled cells in the implanted brain was less than 1Â10 6 in each rat. Thus, the data are only a good indicator to show the difference between the Ad-VEGF and Ad-VEGF-EGFP groups. 17 In agreement with previous studies and on the basis of the results of this study, the mechanisms of the neuroprotective effect of the VEGF-expressing HUMSCs may include the following: (1) release of VEGF, which is neuroprotective to DA neurons, directly acting on target cells; 16, 29, 30 (2) replacement of the degenerated DA neurons by HUMSCs in the SNc; (3) activity of gliocytes and the increased glial cell line-derived neurotrophic factor level; 16 (4) promotion of the levels of possible neuroprotective trophic factors; 31 and (5) antiinflammatory functionality. 32, 33 In summary, this study shows that VEGF-expressing HUMSCs make a significant behavioral improvement in a chronic PD model, which is more significant than HUMSC transplantation alone and corresponds to TH immunoreactivity in the striatum and SNc. Importantly, VEGF expression enhanced the neuroprotective effects by promoting dopaminergic neuron-orientated differentiation of the HUMSCs. Therefore, transplantation of VEGF-expressing HUMSCs represents a novel stem cell engineering-based therapeutic approach for the treatment of PD.
MATERIALS AND METHODS
Isolation and identification of HUMSCs
Preparation of HUMSCs. The experiments described in this study were approved by the Ethical Committee of Tongji Medical College, Huazhong University of Science and Technology, China (HUST). With the permission of the parturient (Gynecology and Obstetrics department, Union Hospital, HUST), umbilical cords were aseptically collected during cesarean sections, stored at 4 1C in 0.01 M sterilized phosphate-buffered solution (PBS) with heparin (20-30 u ml À1 ) until further processing. To avoid endothelial cell contamination, umbilical arteries and vein were removed and the cords were cut into small pieces (0.5-1 cm). Subsequently, the cords were further cut into 1-2 mm 3 fragments and the explants were transferred into six-well plates containing DMEM/F12 (Invitrogen, Carlsbad, CA, USA), along with 20% fetal bovine serum (Invitrogen) and 10 ng per ml of basic fibroblast growth factor (Peprotech, Rocky Hill, NJ, USA). Cultures were maintained at 37 1C in a humidified atmosphere containing 5% CO 2 . The fragments were left undisturbed for 10-12 days to allow cells to migrate from the explants. They were re-fed every 48-72 h and passaged (1:3) by trypsin (0.25%, Invitrogen) digestion until cells reached 80-90% confluency. Immunofluorescence. HUMSCs grown on coverslips were fixed in 4% paraformaldehyde for 30 min at 4 1C, washed with PBS and permeabilized with 0.1% Triton-X100 (Amresco, Solon, OH, USA) and 5% bovine serum albumin (Invitrogen) in PBS, followed by an overnight incubation (at 4 1C) with monoclonal antibodies against CD34, CD44 and CD45 (1:100 dilution, Santa Cruz). 34 The corresponding secondary FITC-conjugated donkey-antimouse IgG (Proteintech, Chicago, IL, USA) diluted 1:100 in PBS was applied for 1 h in darkness at room temperature. Cells were visualized under an epifluorescent microscope (Olympus, Japan).
Ultrastructure of the HUMSCs. After being harvested by 0.25% trypsin digestion, HUMSCs were washed twice (1000 r.p.m., 5 min) in PBS and fixed in 0.01 M PBS containing 2.5% glutaraldehyde. 17 The fragments were postfixed in 1% osmium tetroxide in the same buffer, dehydrated in graded alcohols, embedded in Epon 812, sectioned with ultramicrotome and stained with uranyl acetate and lead citrate. The sections were examined with a transmission electron microscope (TEM; Technai 10, Philips, The Netherlands).
Differentiation studies. Differentiation of HUMSCs was assessed in cultures of the fifth passage. The cells were cultured in a medium that contained osteogenic (10 À7 mol l À1 dexamethasone, 10 mM b-glycerophosphate and 50 mg l À1 ascorbate-phosphate), adipogenic (10 À6 mol l À1 dexamethasone and 10 mg l À1 Insulin) or neurogenic (DMEM/F12 with 0.5% B27, 1% fetal bovine serum, 5% horse serum, 0.5 mM retinoic acid, 20 ng per ml of epidermal growth factor, 50 ng per ml of basic fibroblast growth factor, 50 ng per ml of nerve growth factor) materials. [35] [36] [37] Regents were mostly ordered from Sigma Aldrich (St Louis, MO, USA), except B27 (Invitrogen), epidermal growth factor and nerve growth factor (Peprotech). Two weeks later, osteogenic differentiation was assessed by Alizarin red staining, and intracellular lipid accumulation was visualized using Oil-Red-O staining and inverted phase contrast microscopy. Differentiated neurocytes from the HUMSCs were confirmed by positive staining with NSE (mouse monoclonal antibody, Abcam, Cambridge, MA, USA), GFAP (mouse monoclonal antibody, Santa Cruz) and Nestin (mouse monoclonal antibody, Santa Cruz), which were detected by immunofluorescence staining and assessed by either fluorescence microscopy or flow cytometry.
Adenovirus infection
Adenoviral vectors and adenovirus infection. The replication-deficient adenovirus vector containing the complementary DNA for VEGF and enhanced green fluorescent protein (Ad-VEGF-EGFP) has been described previously. 38 The replication-deficient adenovirus vector that carried the EGFP gene was used as a control. HUMSCs were seeded at a density of 5Â10 5 cells per well of a six-well cell culture plate. HUMSCs were exposed to infectious viral particles in 1 ml serum-free DMEM/F12 at 37 1C medium for 2 h. HUMSCs were infected by Ad-VEGF-EGFP or Ad-EGFP at a MOI of 0, 10, 20, 50, 100, 200 and 400 plaque-forming units per cell. Subsequently, the normal medium was added to the plates for 48 h incubation. Thereafter, HUMSCs were used for transplantation or immunostaining and the medium was used for the VEGF enzyme-linked immunosorbent assay test.
In vitro and in vivo expression of VEGF and EGFP. After 48 h of infection, the efficiency of infection of adenovirus was investigated by flow cytometric detection of the EGFP marker. The MTT colorimetric assay was used to evaluate the effect of VEGF gene transfection on the proliferation of HUMSCs. 39, 40 The coexpression of VEGF (mouse monoclonal antibody, Millipore, Billerica, MA, USA) and EGFP was observed under a confocal microscope by immunofluorescent staining. VEGF secretion from HUMSCs into culture medium and striatal VEGF levels were spectrophotometrically measured at 450 and 570 nm by an enzyme-linked immunosorbent assay kit according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). 41 Basal media were also analyzed as a negative control.
Rodent hemiparkinsonian model and transplantation
Rotenone-induced hemiparkinsonian rat model. A rotenone-induced slowly progressive hemiparkinsonian rat model was chosen for this study. 17 Briefly, inbred adult female Sprague-Dawley rats (220-260 g; from the Center of Experimental Animals, Tongji Medical College, HUST; 12-h light/dark cycles, 22 ± 2 1C, 60 ± 5% humidity; standard laboratory chow and water ad libitum) were anesthetized with chloral hydrate (400 mg kg À1 in 0.9% NaCl, I.P.) and fastened to a cotton bed over a stereotaxic frame (RWD Life Science, Shenzhen, China). Rotenone dissolved in DMSO was infused into the right VTA VEGF-expressing HUMSC treatment for PD N Xiong et al
